Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$1.46 -3.9%	$1.26	$0.87 ▼ $6.78	$145.99M	0.71	846,320 shs	494,490 shs
IPA ImmunoPrecise Antibodies	$1.01 +6.7%	$0.55	$0.27 ▼ $1.07	$46.22M	0.12	2.48 million shs	1.78 million shs
MOLN Molecular Partners	$3.75 -0.3%	$3.90	$3.36 ▼ $12.70	$154.23M	1.11	17,353 shs	449 shs
SLN Silence Therapeutics	$5.66 +5.4%	$4.39	$1.97 ▼ $22.47	N/A	1.41	303,813 shs	108,614 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	-9.88%	+6.57%	+8.15%	-65.73%
IPA ImmunoPrecise Antibodies	0.00%	+38.38%	+106.08%	+138.66%	-1.86%
MOLN Molecular Partners	0.00%	-3.85%	-4.82%	-4.58%	-52.89%
SLN Silence Therapeutics	0.00%	+1.25%	+10.12%	+58.99%	-70.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALEC Alector	3.3474 of 5 stars	3.1	1.0	4.5	2.1	1.7	0.0
IPA ImmunoPrecise Antibodies	2.059 of 5 stars	3.5	3.0	0.0	2.0	0.0	0.6
MOLN Molecular Partners	3.0341 of 5 stars	3.8	5.0	0.0	2.6	0.0	0.6
SLN Silence Therapeutics	2.8398 of 5 stars	3.4	4.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.14	Hold	$4.00	173.97% Upside
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	296.04% Upside
MOLN Molecular Partners	3.50	Strong Buy	$12.00	220.00% Upside
SLN Silence Therapeutics	2.71	Moderate Buy	$33.83	497.76% Upside

Current Analyst Ratings Breakdown

Latest IPA, MOLN, SLN, and ALEC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/13/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
5/9/2025	ALEC Alector	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
5/9/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$4.00 ➝ $3.00
5/9/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $25.00
5/9/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $35.00
4/11/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/1/2025	IPA ImmunoPrecise Antibodies	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Speculative Buy ➝ Speculative Buy	$3.00 ➝ $3.00
3/31/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$100.56M	1.45	N/A	N/A	$1.29 per share	1.13
IPA ImmunoPrecise Antibodies	$18.16M	2.55	N/A	N/A	$0.93 per share	1.09
MOLN Molecular Partners	$5.65M	26.80	N/A	N/A	$3.99 per share	0.94
SLN Silence Therapeutics	$43.26M	N/A	N/A	N/A	$4.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$119.05M	-$1.26	N/A	N/A	N/A	-139.74%	-100.58%	-25.15%	8/6/2025 (Estimated)
IPA ImmunoPrecise Antibodies	-$20.13M	-$1.16	N/A	N/A	N/A	-190.76%	-88.87%	-49.26%	7/3/2025 (Estimated)
MOLN Molecular Partners	-$61.39M	-$1.92	N/A	N/A	N/A	-1,043.01%	-42.20%	-38.12%	8/25/2025 (Estimated)
SLN Silence Therapeutics	-$45.31M	-$1.50	N/A	N/A	N/A	-260.55%	-56.17%	-33.96%	8/15/2025 (Estimated)

Latest IPA, MOLN, SLN, and ALEC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	MOLN Molecular Partners	-$0.3855	-$0.50	-$0.1145	-$0.50	N/A	N/A
5/8/2025	Q1 2025	SLN Silence Therapeutics	-$0.18	-$0.60	-$0.42	-$0.60	$3.58 million	$0.14 million
3/28/2025	Q3 2025	IPA ImmunoPrecise Antibodies	-$0.06	-$0.06	N/A	-$0.46	$6.59 million	$4.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.10	3.34	3.34
IPA ImmunoPrecise Antibodies	0.45	2.32	2.11
MOLN Molecular Partners	N/A	15.28	15.28
SLN Silence Therapeutics	N/A	8.81	8.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
IPA ImmunoPrecise Antibodies	6.70%
MOLN Molecular Partners	26.55%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
ALEC Alector	9.10%
IPA ImmunoPrecise Antibodies	6.83%
MOLN Molecular Partners	5.93%
SLN Silence Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	99.99 million	90.89 million	Optionable
IPA ImmunoPrecise Antibodies	80	45.76 million	42.64 million	Not Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
SLN Silence Therapeutics	100	N/A	N/A	Not Optionable

IPA, MOLN, SLN, and ALEC Headlines

Recent News About These Companies

Wall Street Zen Upgrades Silence Therapeutics (NASDAQ:SLN) to "Hold"

June 16, 2025 | americanbankingnews.com

Silence Therapeutics' (SLN) "Buy" Rating Reiterated at Chardan Capital

June 16, 2025 | americanbankingnews.com

Silence Therapeutics' (SLN) "Buy" Rating Reaffirmed at HC Wainwright

June 15, 2025 | americanbankingnews.com

Silence Therapeutics (NASDAQ:SLN) Rating Increased to Hold at Wall Street Zen

June 14, 2025 | marketbeat.com

HC Wainwright Reiterates "Buy" Rating for Silence Therapeutics (NASDAQ:SLN)

June 13, 2025 | marketbeat.com

Silence Therapeutics (NASDAQ:SLN) Receives Buy Rating from Chardan Capital

June 13, 2025 | marketbeat.com

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

June 12, 2025 | businesswire.com

Brokerages Set Silence Therapeutics plc (NASDAQ:SLN) PT at $33.83

June 10, 2025 | americanbankingnews.com

Silence Therapeutics plc (NASDAQ:SLN) Receives Average Rating of "Moderate Buy" from Analysts

June 7, 2025 | marketbeat.com

Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet

June 6, 2025 | zacks.com

Silence Therapeutics plc (NASDAQ:SLN) Short Interest Update

June 4, 2025 | marketbeat.com

Millennium Management LLC Reduces Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

June 1, 2025 | marketbeat.com

Silence Therapeutics plc (NASDAQ:SLN) Shares Acquired by Bank of America Corp DE

June 1, 2025 | marketbeat.com

Silence Therapeutics plc (NASDAQ:SLN) Shares Bought by Woodline Partners LP

May 27, 2025 | marketbeat.com

Point72 Asset Management L.P. Has $4.36 Million Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

May 22, 2025 | marketbeat.com

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

May 21, 2025 | zacks.com

Silence Therapeutics plc GAAP EPS of -C$0.20

May 8, 2025 | seekingalpha.com

Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | finanznachrichten.de

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | businesswire.com

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

April 23, 2025 | insidermonkey.com

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 5, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Broadcom Earnings Preview: AVGO Stock Near Record Highs
By Leo Miller | June 3, 2025
View Broadcom Earnings Preview: AVGO Stock Near Record Highs

IPA, MOLN, SLN, and ALEC Company Descriptions

Alector NASDAQ:ALEC

$1.46 -0.06 (-3.95%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.44 -0.02 (-1.10%)

As of 06/18/2025 07:56 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

ImmunoPrecise Antibodies NASDAQ:IPA

$1.01 +0.06 (+6.73%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.00 -0.01 (-0.50%)

As of 06/18/2025 07:58 PM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Molecular Partners NASDAQ:MOLN

$3.75 -0.01 (-0.27%)

Closing price 06/18/2025 03:39 PM Eastern

Extended Trading

$3.82 +0.07 (+1.87%)

As of 06/18/2025 04:04 PM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Silence Therapeutics NASDAQ:SLN

$5.66 +0.29 (+5.40%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$5.61 -0.05 (-0.87%)

As of 06/18/2025 04:56 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time